Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.
HUMACAO, PR, July 7, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that it has entered a pharmaceutical product Development Agreement with Glatt Air Techniques, Inc. (“Glatt”).
The Development Agreement solidifies our strong partnership with Glatt, a world class manufacturing firm specializing in pharmaceutical and other industries, for scientific and manufacturing services for the first of our drug deployments “Instaprin”, our road delivery aspirin-based product.
Kraig Higginson, Executive Chairman, stated, “I have been so impressed with the manufacturing and scientific expertise and top-notch facilities that Glatt has utilized in the work they have done with us so far. We look forward to a great future together as we bring Instaprin to the world.”
About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
About Glatt Air Techniques, Inc. Based in Ramsey, New Jersey, Glatt focuses on product development and manufacturing optimization for granules used in the nutritional, food, feed, pharmaceutical and fine chemicals markets. For more information, please visit www.glatt.com.
Safe Harbor Statement. Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Aspire Biopharma, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward- looking statements can be found in the Company’s Form CF and Form D, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether because of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.